Quick Answer
Yes, Medicare Part B covers Visco-3 injections for knee osteoarthritis when medical necessity criteria are met. Visco-3 is a three-injection sodium hyaluronate series designed to supplement the natural fluid in your knee joint. Most patients pay 20% coinsurance after meeting their Part B deductible.
Medicare Part B Coverage for Visco-3
Visco-3 is a sodium hyaluronate viscosupplement that is administered as a series of three weekly injections. Medicare covers Visco-3 under Part B (the medical benefit) because it is given by a healthcare provider in a clinical setting, not self-administered at home.
Key coverage facts:
- Covered under Part B as a physician-administered injectable
- No prior authorization required under Original Medicare
- Subject to Local Coverage Determinations (LCDs) from your regional MAC
- Must meet medical necessity criteria documented in your medical records
- 3-injection series provides a structured treatment course over 3 weeks
Coverage Requirements
Medical Necessity Criteria
For Medicare to pay for Visco-3, your medical records must show:
- Diagnosis of knee osteoarthritis with ICD-10 code M17.x
- Failure of conservative treatment for at least 3 months, including physical therapy, NSAIDs, or activity modification
- Chart documentation showing these treatments were not sufficient
- X-ray evidence confirming osteoarthritis (most MACs require imaging within the past 12 months)
Billing Codes
| Code | Description | 2026 Estimated Allowable |
|---|---|---|
| J7321 | Visco-3 (sodium hyaluronate), per dose | $150 - $250 per injection |
| 20610 | Arthrocentesis, large joint (knee) | $85 - $110 |
| 77002 | Fluoroscopic guidance (if used) | $75 - $95 |
Your provider bills Medicare using J-code J7321 for each Visco-3 injection. This code is billed three times over the treatment course (once per weekly injection).
Frequency Limits
- Medicare typically covers one treatment course (3 weekly injections) per knee every 6 months
- Some MACs allow repeat treatment after 6 months if the initial series provided meaningful relief
- Bilateral knee treatment is generally covered when both knees have documented OA
- Your provider should document the clinical response to support repeat courses
Your Out-of-Pocket Costs
| Item | Amount |
|---|---|
| Part B deductible (2026) | $257/year |
| Coinsurance | 20% of Medicare-approved amount |
| Typical total patient cost | $100 - $200 per treatment course |
| With Medigap | May cover the 20% coinsurance |
Example Cost Calculation
If Medicare approves $200 per injection for a 3-injection course ($600 total):
- Medicare pays: $480 (80%)
- You pay: $120 (20%)
- If you have a Medigap plan: your supplement may cover some or all of that $120
Medicare Advantage Plans
If you have a Medicare Advantage (Part C) plan:
- Coverage generally follows Original Medicare guidelines
- Prior authorization may be required — check with your plan before scheduling
- Copays vary by plan and may differ from the standard 20% coinsurance
- Network restrictions may apply — verify your provider is in-network
- Contact your plan’s member services for specific coverage information
What If Medicare Denies Coverage?
If your Visco-3 claim is denied:
- Request the denial reason in writing
- Gather supporting documents including X-rays, treatment records, and your provider’s letter of medical necessity
- File a redetermination (Level 1 appeal) within 120 days
- Include clinical evidence that viscosupplementation is medically appropriate for your condition
Many initial denials are overturned on appeal with proper documentation.
Visco-3 Product Details
| Feature | Detail |
|---|---|
| Manufacturer | Anika Therapeutics |
| Active ingredient | Sodium hyaluronate |
| Injection schedule | 3 injections, given 1 week apart |
| FDA-approved for | Knee osteoarthritis |
| Molecular weight | Medium range |
| Source | Avian-derived |
| Volume per injection | 2.5 mL |
Visco-3 offers a straightforward three-injection treatment course. Its defined schedule (exactly 3 injections, one per week) provides clarity for both patients and providers about the expected treatment timeline.
Frequently Asked Questions
How often will Medicare pay for Visco-3?
Medicare generally covers one Visco-3 treatment course (3 weekly injections) per knee every 6 months. Your provider must document medical necessity and clinical benefit from prior courses.
Do I need prior authorization for Visco-3 under Medicare?
No. Original Medicare does not require prior authorization for Visco-3. Medicare Advantage plans may have their own prior authorization requirements. Verify with your plan before scheduling.
Is Visco-3 covered under Medicare Advantage?
Yes. Medicare Advantage plans must cover everything Original Medicare covers. Your plan may have different cost-sharing, network restrictions, or prior authorization rules. Contact your plan for details.
How does Visco-3 compare to single-injection HA products?
Visco-3 requires 3 weekly office visits, while single-injection products (like Synvisc-One, Monovisc, or Durolane) need only one visit. Some patients prefer the convenience of a single injection, while others and their providers prefer spreading the treatment over multiple visits. Medicare covers both approaches.
What is the difference between Visco-3 and other 3-injection HA products?
Several HA products use a 3-injection protocol, including Visco-3 and Euflexxa. They differ in molecular weight, source material, and manufacturing process. Your provider can help determine which option is best for your situation. All FDA-approved HA products are covered by Medicare.